Please assess the completion status of the following clinical trial:

Trial Title: Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients 18 years of age or older, with biopsy proven T3-4N0-2M0 rectal cancer are eligible.~* Life expectancy of at least 2 years.~* Zubrod performance status of 0-2.~* Patients must be able to sign an informed consent.~* Adequate bone marrow function: peripheral granulocyte count of \> 1,500 cells/mm3 and platelet count \>100,000/mm3, hemoglobin \> 10 gm/dl and absence of a regular red blood cell transfusion requirement.~* Adequate hepatic function with a total serum bilirubin \< 1.5 x ULN; alkaline phosphatase, alanine aminotransferase (ALAT), and aspartate aminotransferase (ASAT) \< 2.5 x the upper limit of normal (ULN); and adequate renal function as defined by a calculated creatinine clearance \> 50 ml/min \[Cockroft-Gault\].~* Other initial cancer diagnosis more than five years ago without evidence of residual or recurrent disease~* Prior diagnosis of squamous or basal cell carcinoma of skin,no active disease at the time of enrollment.~Exclusion Criteria:~* Known metastases~* Pregnant or lactating women. Women/men of childbearing potential not using a reliable and appropriate contraceptive method.~* May receive no other concurrent chemotherapy or radiation therapy during this trial.~* Severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections~* Prior pelvic radiation~* Known active inflammatory bowel disease, Crohn's disease or ulcerative colitis.~* Medical conditions that would preclude the patient from definitive surgery at the end of concurrent chemoradiation~* Serious, uncontrolled, concurrent infection(s).~* Prior severe reaction to fluoropyrimidine therapy, or known hyper-sensitivity to 5-fluorouracil or known dihydropyrimidine dehydrogenase (DPD) deficiency.~* Treatment for other carcinomas within the last five years, except cured non-melanoma skin and treated in-situ cervical cancer.~* Participation in any investigational drug study within 4 weeks preceding the start of study treatment.~* Clinically significant cardiac disease or myocardial infarction within the last 12 months.~* History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of oral drug intake.~* Other serious uncontrolled medical conditions that the investigator feels might compromise study participation.~* Major surgery \<4 weeks of the start of study treatment, without complete recovery.~* Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome.~* Known, existing uncontrolled coagulopathy~* Any of the following laboratory values:~  * Abnormal hematologic values (neutrophils \< 1.5 x 10\^9/L, platelet count \< 100 x 10\^9/L, hemoglobin \< 10 gm/dl)~ * Impaired renal function (estimated creatinine clearance \<50 ml/min as calculated with Cockroft-Gault equation.~ * Serum total bilirubin \> 1.5 x upper normal limit.~ * ALAT, ASAT \> 2.5 x upper normal limit (or \> 5 x upper normal limit in the case of liver metastases).~ * Alkaline phosphatase \> 2.5 x upper normal limit (or \> 5 x upper normal limit in the case of liver metastases or \> 10 x upper normal limit in the case of bone disease).~* Unwillingness to give written informed consent.~* Unwillingness to participate or inability to comply with the protocol for the duration of the study.~* History of allergic reactions, hypersensitivity reactions to aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), or sulfonamides

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy, Celecoxib, and Radiation (Type: EXPERIMENTAL): Oxaliplatin weekly at 50 mg/m2 given intravenously over two hours for the duration of radiation.~Capecitabine: on the days of radiation at 850 mg/m2 orally twice a day \[1700 mg/m2/day\] (Monday through Friday during radiation therapy).~Celecoxib at 200 mg orally twice a day throughout the duration of radiation without a break.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues